MAM
PVLA

Meeder Asset Management’s Palvella Therapeutics PVLA Stock Holding History

Meeder Asset Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-36
Closed -$9K – 2411
2020
Q2 		$9K Hold
36
– – ﹤0.01% 1366
2020
Q1 		$6K Sell
36
-125
-78% -$31.5K ﹤0.01% 1735
2019
Q4 		$47K Sell
161
-132
-45% -$36.6K ﹤0.01% 1036
2019
Q3 		$80K Buy
293
+240
+453% +$92.9K 0.01% 867
2019
Q2 		$20K Buy
53
+33
+165% +$9.84K ﹤0.01% 1245
2019
Q1 		$5K Sell
20
-56
-74% -$13.3K ﹤0.01% 1412
2018
Q4 		$16K Sell
76
-34
-31% -$10.5K ﹤0.01% 1130
2018
Q3 		$50K Sell
110
-6
-5% -$2.61K ﹤0.01% 788
2018
Q2 		$46.9K Buy
116
+95
+452% +$45.2K ﹤0.01% 771
2018
Q1 		$11K Buy
21
+10
+91% +$6.19K ﹤0.01% 1047
2017
Q4 		$6K Buy
+11
New +$5.11K ﹤0.01% 1279

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Meeder Asset Management's PVLA Position: Q3 2020 in Review

Meeder Asset Management sold out of Palvella Therapeutics (PVLA) in Q3 2020, closing a stake of 36 shares — an estimated $9K sold.

Meeder Asset Management first reported a position in PVLA in Q4 2017 and held it in 11 quarters. The position peaked at $80K in Q3 2019. 88 funds tracked by Wall St. Rank hold PVLA as of Q3 2020.

  • Meeder Asset Management reported no remaining Palvella Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Meeder Asset Management sold 36 Palvella Therapeutics shares in Q3 2020, an estimated $9K.
  • Meeder Asset Management first reported a position in Palvella Therapeutics in Q4 2017 and held it in 11 quarters.
  • Meeder Asset Management's Palvella Therapeutics position peaked at $80K in Q3 2019.
  • 88 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2020.

Based on Meeder Asset Management's 13F filing for Q3 2020, filed 2 Nov 2020.